A. Marshall

发表

Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.

M. Alavi, G. Dore, L. Degenhardt, 2021, The International journal on drug policy.

Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.

Lisa P. Barrett, L. Taylor, C. Treloar, 2016, CMAJ open.

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.

J. Lazarus, R. Marinho, S. Olafsson, 2018, The lancet. Gastroenterology & hepatology.

The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.

J. Lazarus, J. Pawlotsky, G. Dore, 2018, Journal of hepatology.

A gender lens is needed in hepatitis C elimination research.

N. Martin, C. Treloar, S. Larney, 2022, The International journal on drug policy.

'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective.

C. Treloar, J. Grebely, A. Marshall, 2022, The International journal on drug policy.

Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment.

M. Alavi, V. Wiseman, G. Dore, 2022, Drug and alcohol dependence.

Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe

J. Lazarus, R. Marinho, S. Olafsson, 2017 .

Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs.

J. Lazarus, C. Treloar, J. Grebely, 2021, The International journal on drug policy.

Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study.

C. Treloar, M. Martinello, G. Matthews, 2022, The International journal on drug policy.

Enhancing engagement in hepatitis C care among people who inject drugs.

C. Treloar, A. Marshall, A. Madden, 2019, Addiction.

Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis.

J. Ward, L. Degenhardt, G. Fontaine, 2022, The lancet. Gastroenterology & hepatology.

Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay

G. Dore, D. Persing, J. Amin, 2018, The Journal of infectious diseases.

Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.

G. Dore, C. Treloar, J. Grebely, 2018, The International journal on drug policy.

People engaged in opioid agonist treatment as a counterpublic during the COVID‐19 pandemic in Australia: A qualitative study

C. Treloar, J. Grebely, A. Conway, 2022, Drug and alcohol review.

A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study

M. Alavi, P. Read, A. Milat, 2022, Viruses.

Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐ and post‐universal access to direct‐acting antiviral treatment in Australia: The LiveRLife study

P. Read, G. Dore, M. Weltman, 2019, Journal of viral hepatitis.

Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.

G. Dore, T. Collie, M. Micallef, 2015, The International journal on drug policy.

'I didn't want to let it go too far.' The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study.

G. Dore, C. Treloar, J. Grebely, 2017, The International journal on drug policy.

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.

G. Dore, D. Persing, J. Amin, 2017, The lancet. Gastroenterology & hepatology.

"It's a revolving door": Ego-depletion among prisoners with injecting drug use histories as a barrier to post-release success

C. Treloar, P. Dietze, M. Stoové, 2022, International Journal of Drug Policy.

Do women with complex alcohol and other drug use histories want women‐only residential treatment?

J. Strang, C. Treloar, C. Tompkins, 2018, Addiction.

Structural competency in the post-prison period for people who inject drugs: A qualitative case study.

C. Treloar, P. Dietze, M. Stoové, 2021, The International journal on drug policy.

'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.

L. Degenhardt, C. Treloar, J. Grebely, 2023, The International journal on drug policy.

Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.

J. Ward, G. Dore, P. Vickerman, 2022, The International journal on drug policy.

Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation.

C. Treloar, J. Grebely, A. Marshall, 2020, The International journal on drug policy.

The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There".

J. Grebely, S. Sagan, J. Feld, 2018, Canadian liver journal.

The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C

J. Grebely, S. Sagan, S. Macparland, 2016, Canadian journal of gastroenterology & hepatology.

Simplifying hepatitis C care models: a crucial step towards hepatitis C elimination.

G. Matthews, A. Marshall, 2022, The lancet. Gastroenterology & hepatology.

Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study.

C. Treloar, P. Dietze, M. Stoové, 2023, Journal of substance use and addiction treatment.

“You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic

G. Dore, L. Degenhardt, C. Treloar, 2023, International Journal of Drug Policy.

Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study.

M. Alavi, G. Dore, J. Amin, 2023, Drug and alcohol review.

V. Wiseman, G. Dore, A. Miners, 2023, Quality of Life Research.

Optimising community health services in Australia for populations affected by stigmatised infections: What do service users want?

C. Newman, L. Brener, A. Marshall, 2022, Health and Social Care in the community.

Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study

C. Treloar, J. Grebely, A. Conway, 2023, Implementation Science.

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.

G. Dore, D. Persing, J. Amin, 2017, The lancet. Gastroenterology & hepatology.

Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience.

C. Treloar, J. Grebely, A. Marshall, 2019, Drug and alcohol dependence.

Perspectives and sentiments on contingency management from people who use methamphetamine.

R. Mcketin, L. Degenhardt, M. Farrell, 2023, Drug and Alcohol Review.